<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35798698</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>Bimodal regulation of axonal transport by the GDNF-RET signalling axis in healthy and diseased motor neurons.</ArticleTitle><Pagination><StartPage>584</StartPage><MedlinePgn>584</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">584</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-022-05031-0</ELocationID><Abstract><AbstractText>Deficits in axonal transport are one of the earliest pathological outcomes in several models of amyotrophic lateral sclerosis (ALS), including SOD1<sup>G93A</sup> mice. Evidence suggests that rescuing these deficits prevents disease progression, stops denervation, and extends survival. Kinase inhibitors have been previously identified as transport enhancers, and are being investigated as potential therapies for ALS. For example, inhibitors of p38 mitogen-activated protein kinase and insulin growth factor receptor 1 have been shown to rescue axonal transport deficits in vivo in symptomatic SOD1<sup>G93A</sup> mice. In this work, we investigated the impact of RET, the tyrosine kinase receptor for glial cell line-derived neurotrophic factor (GDNF), as a modifier of axonal transport. We identified the fundamental interplay between RET signalling and axonal transport in both wild-type and SOD1<sup>G93A</sup> motor neurons in vitro. We demonstrated that blockade of RET signalling using pharmacological inhibitors and genetic knockdown enhances signalling endosome transport in wild-type motor neurons and uncovered a divergence in the response of primary motor neurons to GDNF compared with cell lines. Finally, we showed that inhibition of the GDNF-RET signalling axis rescues in vivo transport deficits in early symptomatic SOD1<sup>G93A</sup> mice, promoting RET as a potential therapeutic target in the treatment of ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rhymes</LastName><ForeName>Elena R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosolini</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0001-7651-7442</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellows</LastName><ForeName>Alexander D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahy</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Alzheimer's Research UK UCL Drug Discovery Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Neil Q</ForeName><Initials>NQ</Initials><AffiliationInfo><Affiliation>Signalling and Structural Biology Laboratory, The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavo</LastName><ForeName>Giampietro</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4319-8745</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK. giampietro.schiavo@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, University College London, London, UK. giampietro.schiavo@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK. giampietro.schiavo@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>(FC001115)</GrantID><Agency>Wellcome Trust (Wellcome)</Agency><Country/></Grant><Grant><GrantID>FC001115</GrantID><Acronym>ARC_</Acronym><Agency>Arthritis Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>543129</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country/></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>520909</GrantID><Agency>Alzheimer's Research UK (ARUK)</Agency><Country/></Grant><Grant><GrantID>(FC001115)</GrantID><Agency>Cancer Research UK (CRUK)</Agency><Country/></Grant><Grant><GrantID>(FC001115)</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country/></Grant><Grant><GrantID>107116/Z/15/Z</GrantID><Agency>Wellcome Trust (Wellcome)</Agency><Country/></Grant><Grant><GrantID>223022/Z/21/Z</GrantID><Agency>Wellcome Trust (Wellcome)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495040">Gdnf protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D051096">Proto-Oncogene Proteins c-ret</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C494999">Ret protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="Y">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051096" MajorTopicYN="Y">Proto-Oncogene Proteins c-ret</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35798698</ArticleId><ArticleId IdType="pmc">PMC9263112</ArticleId><ArticleId IdType="doi">10.1038/s41419-022-05031-0</ArticleId><ArticleId IdType="pii">10.1038/s41419-022-05031-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maday S, Twelvetrees AE, Moughamian AJ, Holzbaur ELF. Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron. 2014;84:292&#x2013;309. doi: 10.1016/j.neuron.2014.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.019</ArticleId><ArticleId IdType="pmc">PMC4269290</ArticleId><ArticleId IdType="pubmed">25374356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological disease. Nat Rev Neurol. 2019;15:691&#x2013;703. doi: 10.1038/s41582-019-0257-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0257-2</ArticleId><ArticleId IdType="pubmed">31558780</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis. 2017;105:283&#x2013;99. doi: 10.1016/j.nbd.2017.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.02.004</ArticleId><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, Kalmar B, Rhymes ER, Fellows AD, Ahmed M, Whiting P, et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596. doi: 10.1038/s41419-018-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0624-8</ArticleId><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, Hafezparast M, Bohnert S, Dick JRT, Martin J, Schiavo G, et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol. 2005;169:561&#x2013;7. doi: 10.1083/jcb.200501085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200501085</ArticleId><ArticleId IdType="pmc">PMC2171702</ArticleId><ArticleId IdType="pubmed">15911875</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Gordon D, Devoy A, Fratta P, Fisher EMC, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30:3655.e2&#x2013;62.e2. doi: 10.1016/j.celrep.2020.02.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.02.078</ArticleId><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosolini AP, Sleigh JN, Surana S, Rhymes ER, Cahalan SD, Schiavo G. BDNF-dependent modulation of axonal transport is selectively impaired in ALS. bioRxiv:2021.12.06.471484 [Preprint]. 2021 [cited 2021 Dec 7]: [11 p.]. Available from https://www.biorxiv.org/content/10.1101/2021.12.06.471484v2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.06.471484v2</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, et al. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006;52:293&#x2013;305. doi: 10.1016/j.neuron.2006.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.08.018</ArticleId><ArticleId IdType="pubmed">17046692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Sahai E, Kelly G, Golding M, Greensmith L, Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci USA. 2010;107:20523&#x2013;8. doi: 10.1073/pnas.1006869107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006869107</ArticleId><ArticleId IdType="pmc">PMC2996651</ArticleId><ArticleId IdType="pubmed">21059924</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;43. doi: 10.1016/j.neuron.2013.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu A, Gradus T, Altman T, Maimon R, Saraf Avraham N, Geva M, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1 G93A model. Cell Death Dis. 2019. 10.1038/S41419-019-1451-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017;8:1&#x2013;15. doi: 10.1038/s41467-016-0009-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-016-0009-6</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, Greensmith L, Schiavo G. Regulation of axonal transport by protein kinases. Trends Biochem Sci. 2015;40:597&#x2013;610. doi: 10.1016/j.tibs.2015.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2015.08.003</ArticleId><ArticleId IdType="pubmed">26410600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhullar KS, Lagar&#xf3;n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48. doi: 10.1186/s12943-018-0804-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0804-2</ArticleId><ArticleId IdType="pmc">PMC5817855</ArticleId><ArticleId IdType="pubmed">29455673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4:387&#x2013;98. doi: 10.1038/nrd1719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1719</ArticleId><ArticleId IdType="pubmed">15864268</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002;21:281&#x2013;93. doi: 10.1093/emboj/21.3.281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/21.3.281</ArticleId><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Bosco DA, Brown H, Gatto R, Kaminska A, Song Y, et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS ONE. 2013;8:e65235. doi: 10.1371/journal.pone.0065235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065235</ArticleId><ArticleId IdType="pmc">PMC3680447</ArticleId><ArticleId IdType="pubmed">23776455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FJ, Hebbar S, Gao XA, Alexander M, Pandey JP, Walla MD, et al. Ndel1 binding to intermediate chains and alters dynein motility. Traffic. 2015;16:941&#x2013;61. doi: 10.1111/tra.12304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tra.12304</ArticleId><ArticleId IdType="pmc">PMC4543430</ArticleId><ArticleId IdType="pubmed">26010407</ArticleId></ArticleIdList></Reference><Reference><Citation>Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet. 2013;22:1783&#x2013;90. doi: 10.1093/hmg/ddt028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt028</ArticleId><ArticleId IdType="pubmed">23364049</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellows AD, Rhymes ER, Gibbs KL, Greensmith L, Schiavo G. IGF 1R regulates retrograde axonal transport of signalling endosomes in motor neurons. EMBO Rep. 2020. 10.15252/embr.201949129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054680</ArticleId><ArticleId IdType="pubmed">32030864</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xe8;s A, Haase G, Airaksinen MS, Livet J, Filippi P, DeLapeyri&#xe8;re O. GFR&#x3b1;1 is required for development of distinct subpopulations of motoneuron. J Neurosci. 2000;20:4992&#x2013;5000. doi: 10.1523/JNEUROSCI.20-13-04992.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-13-04992.2000</ArticleId><ArticleId IdType="pmc">PMC6772293</ArticleId><ArticleId IdType="pubmed">10864957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, Jeon GS, Cashman NR, Kowall NW, Lee J. Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS. Lab Invest. 2011;91:342&#x2013;52. doi: 10.1038/labinvest.2010.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2010.203</ArticleId><ArticleId IdType="pmc">PMC3085919</ArticleId><ArticleId IdType="pubmed">21283077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Mitsuma N, Inukai A, Ito Y, Li M, Mitsuma T, et al. Expression of GDNF and GDNFR-A mRNAs in muscles of patients with motor neuron diseases. Neurochem Res. 1999;24:785&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10447463</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Feng Y, Xue Y, Zhan X, Fu Y, Gui G, et al. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Mol Neurodegener. 2022;17:8. 10.1186/s13024-021-00510-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8751314</ArticleId><ArticleId IdType="pubmed">35012575</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe Y, Nagano I, A Gazi MS, Murakami T, Shiote M, Shoji M, et al. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Apoptosis. 2002;7:329&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12101392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosolini AP, Sleigh JN. Motor neuron gene therapy: lessons from spinal muscular atrophy for amyotrophic lateral sclerosis. Front Mol Neurosci. 2017;10:405. doi: 10.3389/fnmol.2017.00405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00405</ArticleId><ArticleId IdType="pmc">PMC5725447</ArticleId><ArticleId IdType="pubmed">29270111</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Alkaslasi M, Vit JP, Lawless G, Godoy M, Gowing G, et al. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1 G93A ALS rat but has adverse side effects. Gene Ther. 2017;24:245&#x2013;52. doi: 10.1038/gt.2017.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2017.9</ArticleId><ArticleId IdType="pmc">PMC5404206</ArticleId><ArticleId IdType="pubmed">28276446</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham Robinett R, Freemerman AJ, Skinner MA, Shewchuk L, Lackey K. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors. Bioorg Med Chem Lett. 2007;17:5886&#x2013;93. doi: 10.1016/j.bmcl.2007.07.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2007.07.104</ArticleId><ArticleId IdType="pubmed">17884497</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt K, Reversi A, Berninghausen O, Hopkins CR, Schiavo G. Neurotrophins redirect p75NTR from a clathrin-independent to a clathrin-dependent endocytic pathway coupled to axonal transport. Traffic. 2007;8:1736&#x2013;49. doi: 10.1111/j.1600-0854.2007.00645.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2007.00645.x</ArticleId><ArticleId IdType="pubmed">17897318</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar M, Charalampopoulos I, Kenchappa RS, Reversi A, Klos-Applequist JM, Karaca E, et al. Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor. J Cell Sci. 2009;122:3351&#x2013;7. doi: 10.1242/jcs.055061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.055061</ArticleId><ArticleId IdType="pmc">PMC2736866</ArticleId><ArticleId IdType="pubmed">19706676</ArticleId></ArticleIdList></Reference><Reference><Citation>Terenzio M, Golding M, Schiavo G. siRNA screen of ES cell-derived motor neurons identifies novel regulators of tetanus toxin and neurotrophin receptor trafficking. Front Cell Neurosci. 2014;8:140. doi: 10.3389/fncel.2014.00140.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00140</ArticleId><ArticleId IdType="pmc">PMC4033017</ArticleId><ArticleId IdType="pubmed">24904285</ArticleId></ArticleIdList></Reference><Reference><Citation>Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, Rossetto O, et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 2012;8:e1003087. doi: 10.1371/journal.ppat.1003087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003087</ArticleId><ArticleId IdType="pmc">PMC3531519</ArticleId><ArticleId IdType="pubmed">23300443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Schiavo G. In vivo imaging of anterograde and retrograde axonal transport in rodent peripheral nerves. Methods Mol Biol. 2020;2143:271&#x2013;92. doi: 10.1007/978-1-0716-0585-1_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0585-1_20</ArticleId><ArticleId IdType="pmc">PMC7116510</ArticleId><ArticleId IdType="pubmed">32524487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosolini AP, Villarroel-Campos D, Schiavo G, Sleigh JN. Expanding the toolkit for in vivo imaging of axonal transport. J Vis Exp. 2021;178:e63471. 10.3791/63471.</Citation><ArticleIdList><ArticleId IdType="pubmed">35001910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, Kalmar B, Sleigh JN, Greensmith L, Schiavo G. In vivo imaging of axonal transport in murine motor and sensory neurons. J Neurosci Methods. 2016;257:26&#x2013;33. doi: 10.1016/j.jneumeth.2015.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2015.09.018</ArticleId><ArticleId IdType="pmc">PMC4666412</ArticleId><ArticleId IdType="pubmed">26424507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinevez JY, Perry N, Schindelin J, Hoopes GM, Reynolds GD, Laplantine E, et al. TrackMate: an open and extensible platform for single-particle tracking. Methods. 2017;115:80&#x2013;90. doi: 10.1016/j.ymeth.2016.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2016.09.016</ArticleId><ArticleId IdType="pubmed">27713081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalevich J, Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013;1078:9&#x2013;21. doi: 10.1007/978-1-62703-640-5_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-640-5_2</ArticleId><ArticleId IdType="pmc">PMC5127451</ArticleId><ArticleId IdType="pubmed">23975817</ArticleId></ArticleIdList></Reference><Reference><Citation>Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of selpercatinib in RET fusion&#x2013;positive non&#x2013;small-cell lung cancer. N Engl J Med. 2020;383:813&#x2013;24. doi: 10.1056/NEJMoa2005653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005653</ArticleId><ArticleId IdType="pmc">PMC7506467</ArticleId><ArticleId IdType="pubmed">32846060</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29:1869. doi: 10.1093/annonc/mdy137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy137</ArticleId><ArticleId IdType="pmc">PMC6096733</ArticleId><ArticleId IdType="pubmed">29912274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14:173&#x2013;86. doi: 10.1038/nrc3680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3680</ArticleId><ArticleId IdType="pubmed">24561444</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4:299&#x2013;309. doi: 10.1038/nrn1078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1078</ArticleId><ArticleId IdType="pubmed">12671646</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheimer O, Cheung N-K, Gerald WL. The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007. 10.1158/1535-7163.MCT-06-0587.</Citation><ArticleIdList><ArticleId IdType="pubmed">17431108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan LM. GDNF and the RET receptor in cancer: new insights and therapeutic potential. Front Physiol. 2019. 10.3389/FPHYS.2018.01873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330338</ArticleId><ArticleId IdType="pubmed">30666215</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, et al. RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements. Cell Rep. 2016;17:3319&#x2013;32. doi: 10.1016/j.celrep.2016.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.11.061</ArticleId><ArticleId IdType="pmc">PMC5199340</ArticleId><ArticleId IdType="pubmed">28009299</ArticleId></ArticleIdList></Reference><Reference><Citation>Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12:192&#x2013;202. doi: 10.1038/nrendo.2016.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.11</ArticleId><ArticleId IdType="pubmed">26868437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Huang EJ. Dynamic expression of neurotrophic factor receptors in postnatal spinal motoneurons and in mouse model of ALS. J Neurobiol. 2006;66:882&#x2013;95. doi: 10.1002/neu.20269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/neu.20269</ArticleId><ArticleId IdType="pmc">PMC3600432</ArticleId><ArticleId IdType="pubmed">16680759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambey PA, Kanwore K, Ayanlaja AA, Nadeem I, Du YZ, Buberwa W, et al. Failure of glial cell-line derived neurotrophic factor (GDNF) in clinical trials orchestrated by reduced NR4A2 (NURR1) transcription factor in Parkinson&#x2019;s disease. A systematic review. Front Aging Neurosci. 2021;13:59. doi: 10.3389/fnagi.2021.645583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.645583</ArticleId><ArticleId IdType="pmc">PMC7943926</ArticleId><ArticleId IdType="pubmed">33716718</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42:581&#x2013;8. doi: 10.1016/0092-8674(85)90115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(85)90115-1</ArticleId><ArticleId IdType="pubmed">2992805</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Menacho I. Structure and function of RET in multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018;25:T79&#x2013;90. doi: 10.1530/ERC-17-0354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-17-0354</ArticleId><ArticleId IdType="pubmed">29175871</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamori S, Matsubara T, Haratake N, Toyokawa G, Fujishita T, Toyozawa R, et al. Targeted therapy for RET fusion lung cancer: breakthrough and unresolved issue. Front Oncol. 2021;11:3272. doi: 10.3389/fonc.2021.704084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.704084</ArticleId><ArticleId IdType="pmc">PMC8419300</ArticleId><ArticleId IdType="pubmed">34497761</ArticleId></ArticleIdList></Reference><Reference><Citation>Arce V, Pollock RA, Philippe JM, Pennica D, Henderson CE, Delapeyri&#xe8;re O. Synergistic effects of Schwann- and muscle-derived factors on motoneuron survival involve GDNF and cardiotrophin-1 (CT-1) J Neurosci. 1998;18:1440&#x2013;8. doi: 10.1523/JNEUROSCI.18-04-01440.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-04-01440.1998</ArticleId><ArticleId IdType="pmc">PMC6792716</ArticleId><ArticleId IdType="pubmed">9454853</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheim RW, Houenou LJ, Parsadanian AS, Prevette D, Snider WD, Shen L. Glial cell line-derived neurotrophic factor and developing mammalian motoneurons: regulation of programmed cell death among motoneuron subtypes. J Neurosci. 2000;20:5001&#x2013;11. doi: 10.1523/JNEUROSCI.20-13-05001.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-13-05001.2000</ArticleId><ArticleId IdType="pmc">PMC6772300</ArticleId><ArticleId IdType="pubmed">10864958</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene. 2000;19:4469&#x2013;75. doi: 10.1038/sj.onc.1203799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1203799</ArticleId><ArticleId IdType="pubmed">11002419</ArticleId></ArticleIdList></Reference><Reference><Citation>Irala D, Bonafina A, Fontanet PA, Alsina FC, Paratcha G, Ledda F. The GDNF-GFR&#x3b1;1 complex promotes the development of hippocampal dendritic arbors and spines via NCAM. Development. 2016;143:4224&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">27707798</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen J, Gotfryd K, Li S, Kulahin N, Soroka V, Rasmussen KK, et al. Role of glial cell line-derived neurotrophic factor (GDNF)&#x2013;neural cell adhesion molecule (NCAM) interactions in induction of neurite outgrowth and identification of a binding site for NCAM in the heel region of GDNF. J Neurosci. 2009;29:11360&#x2013;76. doi: 10.1523/JNEUROSCI.3239-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3239-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665939</ArticleId><ArticleId IdType="pubmed">19741142</ArticleId></ArticleIdList></Reference><Reference><Citation>Paratcha G, Ledda F, Ib&#xe1;&#xf1;ez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell. 2003;113:867&#x2013;79. doi: 10.1016/S0092-8674(03)00435-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00435-5</ArticleId><ArticleId IdType="pubmed">12837245</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwase T, Jung CG, Bae H, Zhang M, Soliven B. Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells. J Neurochem. 2005;94:1488&#x2013;99. doi: 10.1111/j.1471-4159.2005.03290.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03290.x</ArticleId><ArticleId IdType="pubmed">16086701</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Sasaki Y, Takei K, Yamamoto H, Shouji M, Sugiyama Y, et al. Correlation between Semaphorin3A-induced facilitation of axonal transport and local activation of a translation initiation factor eukaryotic translation initiation factor 4E. J Neurosci. 2004;24:6161. doi: 10.1523/JNEUROSCI.1476-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1476-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729675</ArticleId><ArticleId IdType="pubmed">15240808</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications for filament toxicity. J Neurosci Res. 2009;87:440&#x2013;51. doi: 10.1002/jnr.21850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21850</ArticleId><ArticleId IdType="pmc">PMC2739042</ArticleId><ArticleId IdType="pubmed">18798283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y, et al. Pathogenic forms of Tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci. 2011;31:9858&#x2013;68. doi: 10.1523/JNEUROSCI.0560-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0560-11.2011</ArticleId><ArticleId IdType="pmc">PMC3391724</ArticleId><ArticleId IdType="pubmed">21734277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>